London startup trials drug to prevent cancer therapy side-effect
Poolbeg Pharma to test the treatment in NHS hospitals and says it is also developing a GLP-1 weight loss pill A London-based startup is about to trial a drug at six NHS hospitals that could stop people on cancer immunotherapy getting a life-threatening side-effect. Poolbeg Pharma said its oral drug POLB 001 could make treatment for blood cancer safer by preventing cytokine release syndrome (CRS) , when the immune system goes into overdrive and attacks the body, leading to org
A London-based startup is set to conduct a trial of a drug at six NHS hospitals. The drug aims to prevent a severe side-effect of cancer immunotherapy known as cytokine storm. Poolbeg Pharma is behind the initiative, which could make blood cancer treatments safer. The drug, POLB 001, is designed to stop the immune system from overreacting. The company is also working on a GLP-1 weight loss pill. This development could significantly improve patient outcomes during cancer treatment. The trial represents a major step forward in managing treatment side-effects.
It has the potential to improve the safety and effectiveness of cancer treatments.
📌 Kaynak
Bu özet World kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →